Overlooked Peptide P3 May Help Drive Alzheimer's, UC Santa Cruz Chemist Argues

The source is a perspective article in the journal ChemBioChem, written by Jevgenij Raskatov of the University of California, Santa Cruz. It is a review and opinion piece, not a new experiment. It sums up lab research, including work from Raskatov's own group, and it involves no patients.

Here is the background. Alzheimer's research has centered on amyloid β (Aβ), a protein fragment that clumps in the brain. It is cut from a larger parent protein by an enzyme called β-secretase. If a different enzyme, α-secretase, cuts the parent protein instead, a shorter fragment called P3 can form.

P3 has received little attention. It is often treated as "nonamyloidogenic and nontoxic," meaning it is assumed not to form the sticky clumps seen in Alzheimer's and not to harm nerve cells.

Raskatov writes that his research, and that of others, shows otherwise. His group named the peptide Amyloid α (Aα). The study says it readily forms oligomers, which are small clusters, and fibrils, which are long threads. It is "potentially neurotoxic." It may also interact with Aβ and change how Aβ clumps together and how toxic it is.

The wording matters. The study says "potentially" and "may." It does not say P3 causes Alzheimer's. It calls for revising the amyloid cascade hypothesis, the longstanding idea that Aβ buildup starts the disease, to include P3. The author calls that revision "urgently needed." The weakest point is that this is one chemist's argument built largely on his own group's lab work, and whether P3 matters in patients is still unknown.

It says P3 forms clumps faster than Aβ and may be less toxic than Aβ. It also says an independent UK group confirmed the findings, according to Raskatov, and that at least four published papers cited his work as showing P3 was harmless. We could not check those points against the full paper. The coverage also quotes Raskatov: "There's still more research to be done. But this could turn Alzheimer's research on its head."

What does this mean for people worried about Alzheimer's? For now, nothing changes in daily life. The evidence is from lab studies, and the study offers no human treatment data. There is no basis here for any change in diet, supplements or habits.

The longer-term question is about treatment. Raskatov argues that the benefits of Aβ-targeting drugs such as lecanemab and donanemab, which have been approved, remain limited. If P3 does contribute to disease in people, therapies that ignore it might miss part of the problem. If it does not, researchers will have ruled out one more suspect. Either answer would sharpen how the field chooses drug targets.

What to watch next

Whether other labs confirm that P3 clumps and harms nerve cells, and whether studies in animals and people show that it plays a real role in Alzheimer's.

Rubedo's Topical Drug Cut Skin Epigenetic Age by 2.1 Years, Company Says Social Security Sets 3.6% Benefit Increase for 2027, Largest Since 2023 Unemployed Workers 55 to 64 Average Over Eight Months Without a Job Alector Prices $75 Million Stock Offering to Fund Neurodegeneration Work CMS Proposes Medicare Advantage Directory and Part D PBM Rules